MeSH tree: D12.776.124.790.651.114.224
Nearly 10,000 cases of advanced bowel cancer are diagnosed in England each year, with cases in young adults rising. There are limited options for treating advanced bowel cancer. Scientists have now developed an AI-powered ...
Apr 14, 2026
0
10
A study published April 10 in The Lancet reports that the anti-PD-1 immunotherapy pembrolizumab (brand name Keytruda) significantly improved overall survival in adults with platinum-resistant ovarian cancer when given as ...
Apr 13, 2026
0
5
Scientists in China have developed a two-antibody cocktail to treat respiratory syncytial virus, or RSV, that in laboratory studies prevented the virus from developing drug resistance—a persistent problem with current therapies ...
Early results from preclinical studies and a clinical trial led by researchers at the UCLA Health Jonsson Comprehensive Cancer Center and Stanford Medicine suggest that combining targeted radiation therapy with an experimental ...
Mar 27, 2026
0
6
Getting a tattoo can be a thrilling, albeit painful, experience. About one-third of Australians have a tattoo, with many getting inked as a rite of passage.
Mar 22, 2026
0
12
Patients with leptomeningeal metastasis (LM) have historically had few treatment options. Now, researchers from The University of Texas MD Anderson Cancer Center have found a combination of targeted therapies, tucatinib and ...
Mar 18, 2026
0
10
Clinically available KRAS inhibitors mainly target G12C, which is rare in PDAC and often acquires resistance. Oncogenic KRAS inactivates RB1 via CDK4/6, while RB1 mutation is rare. Thus, CDK4/6 inhibition offers an indirect ...
Mar 13, 2026
0
9
Individuals with one to three allergenic foods are able to introduce and continue eating allergenic foods at 12 months after multifood oral immunotherapy (mOIT) or omalizumab, according to a study presented at the annual ...
Mar 6, 2026
0
11
For patients with asthma, receipt of immune checkpoint inhibitor (ICI) therapy for melanoma or renal cell carcinoma is not associated with an increased risk for exacerbations, according to a study presented at the annual ...
Mar 5, 2026
0
4
Twenty years. That's how long Robert Oman has been cancer-free, thanks to a clinical trial offered at the University of Rochester's Wilmot Cancer Institute. And he isn't alone: 70% of patients in the trial who had advanced-stage ...
Mar 1, 2026
0
25
